Invesco Ltd. Buys 23,852 Shares of Agios Pharmaceuticals, Inc. $AGIO

Key Points

• Invesco Ltd. increased its stake in Agios Pharmaceuticals by 28.6%, acquiring an additional 23,852 shares during the 1st quarter, bringing its total ownership to approximately 107,367 shares valued at $3,146,000.
• Analysts have mixed ratings for Agios Pharmaceuticals, with one firm downgrading the stock to a "sell" and others adjusting target prices, resulting in a current average rating of "Moderate Buy" with a target price of $56.33.
• Insider selling activity has been reported, with notable sales including Sarah Gheuens selling 11,914 shares, reflecting a 16.28% decrease in her ownership of the company’s stock.

Invesco Ltd. boosted its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 28.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 107,367 shares of the biopharmaceutical company's stock after buying an additional 23,852 shares during the quarter. Invesco Ltd. owned approximately 0.19% of Agios Pharmaceuticals worth $3,146,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Jefferies Financial Group Inc. bought a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at about $49,290,000. Paradigm Biocapital Advisors LP bought a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at $9,084,000. Deutsche Bank AG boosted its stake in Agios Pharmaceuticals by 39.7% during the 4th quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock valued at $30,732,000 after purchasing an additional 265,637 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Agios Pharmaceuticals by 207.6% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 386,523 shares of the biopharmaceutical company's stock worth $11,325,000 after purchasing an additional 260,845 shares during the last quarter. Finally, Casdin Capital LLC purchased a new stake in Agios Pharmaceuticals in the 4th quarter valued at $8,215,000.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,770 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $92,905.80. Following the completion of the sale, the insider directly owned 26,122 shares in the company, valued at $876,131.88. This represents a 9.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Sarah Gheuens sold 11,914 shares of the stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $37.99, for a total value of $452,612.86. Following the sale, the insider directly owned 61,271 shares of the company's stock, valued at approximately $2,327,685.29. This trade represents a 16.28% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 57,448 shares of company stock worth $2,026,141 in the last quarter. 4.93% of the stock is owned by company insiders.

Agios Pharmaceuticals Price Performance

Shares of Agios Pharmaceuticals stock traded up $0.85 during trading hours on Wednesday, reaching $40.10. The company had a trading volume of 403,610 shares, compared to its average volume of 701,299. The business has a fifty day simple moving average of $37.33 and a 200 day simple moving average of $33.12. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58. The firm has a market cap of $2.33 billion, a PE ratio of 3.64 and a beta of 0.87.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). The firm had revenue of $12.50 million for the quarter, compared to analysts' expectations of $9.46 million. Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. On average, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Bank of America decreased their price objective on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Scotiabank reduced their target price on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a report on Monday, July 28th. Finally, Wall Street Zen lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $56.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.